Evidence Table N1. Articles/arms for class OTHER.

Comp-Trial		TARGET HEADING Treatment	Dose, route, frequency	Comments, ancillary treatment	COMPARATOR Treatment	Dose, route, frequency	Comments, ancillary treatment	Outcome Table(s)
N.01.01	266	**Sunder vati**	500 mg oral tid.	*Mild soap and water.*	**Placebo**	500 mg oral tid.	*Mild soap and water.*	Continuous (M)
N.01.02	325	**Gugulipid**	25 mg oral bid.	*Gugulipid is standardized extract of Commiphora Mutrel, an Indian medicinal plant.*	**Tetracycline**	500 mg oral bid.		Continuous Discrete
N.01.03	94	**Isolutrol**	0.15 % topical (can't say)	*Frequency and dose unknown; deep sea shark liver oil.*	**Benzoyl peroxide**	5 % topical (can't say)		Continuous Discrete
N.01.04	17	**Ocimum basilicum**	No dose information.	*Leaves crushed in palm and juice applied at night as thin smear over lesions. Mild soap in morning.*	**Tetracycline**	500 mg oral bid.	*Dose maintained or reduced at 4 weeks depending on response. Sulfur lotion twice a day after washing with mild soap.*	Discrete
N.01.05	18	**Tea tree oil**	5 % topical (can't say)	*Melaleuca alternifolia.*	**Benzoyl peroxide**	5 % topical ()		Continuous Discrete
N.02.01	175	**Clobetasol propionate**	No dose information.	*To one side of the face.*	**Vehicle**	No dose information		Continuous Discrete
N.02.03	288	**Hydrocortisone**	1 topical bid.		**Hydrocortisone**	1 % topical bid.		Discrete (M)
					Sulphur	4 % topical bid.		
N.02.04	228	**Methylprednisolone**	2.5 % topical bid.		**Vehicle**	No dose information		Discrete
		Neomycin	2.5 % topical bid.					
N.02.05	102	**Sulphur**	5 % topical (can't say)		**Vehicle**	No dose information		Discrete
		Neomycin	0.25 % topical (can't say)					
		Methylprednisolone	0.25 % topical (can't say)					
	346	**Aluminum chlorhydroxide**	10 % topical qd.		**Placebo**	No dose information	*Vehicle for Neo-Medrol®. Physically*	Discrete

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
		Sulfur	5 % topical qd.				*distinguishable from active drug.*	
		Methylprednisolone	0.25 % topical qd.					
		Neomycin	0.25 % topical qd.					
N.02.06	**228**	**Methylprednisolone**	2.5 % topical bid.		**Sulphur**	50 % topical bid.	*Modified placebo.*	Discrete
		Neomycin	2.5 % topical bid.		**Aluminum chlorhydroxide**	100 % topical bid.		
	347	**Aluminum chlorhydroxide**	10 % topical qd.		**Sulfur**	5 % topical qd.	*Physically indistinguishable from Neo-Medrol®.*	Discrete
		sulfur	0.25 % topical qd.					
		Methylprednisolone	0.25 % topical qd.					
		Neomycin	0.25 % topical qd.					
N.03.01	**189**	**Gamma-globulin**	2 cc other (q 2 weeks)	*Usual therapeutic measures.*	**Placebo**	2 cc other (q 2 weeks)	*Colored to look like gamma globulin.*	Discrete
N.03.02	**15**	**Unfractionated human dialyzable transfer factor**	No dose information.	*preparation of Tfd: human leucocyte dialysate was prepared from a pool of citrated buffy coats obtained from the Finnish Red Cross Blood Transfusion Service and fractionated on Sephadex® G-10 as previously described (Ashorn, R. Acta. Pathol. Microbiol Scand ICI 1982; 90: 331-7). Soap/low pH cleanser (average), and, if necessary, a cream containing salicylic acid and sulfur.*	**Fractionated human dialyzable transfer factor**	No dose information	*preparation of Tfd: human leucocyte dialysate was prepared from a pool of citrated buffy coats obtained from the Finnish Red Cross Blood Transfusion Service and fractionated on Sephadex® G-10 as previously described (Ashorn, R. Acta. Pathol. Microbiol Scand ICI 1982; 90: 331-7). Soap/low pH cleanser (average), and, if necessary, a cream containing salicylic acid and sulfur.*	Discrete
N.03.03	**222**	**Staphylococcal**	0.5 ml other (q 4	*.1 ml, .2 ml, .4 ml, .8 ml &*	**Vehicle**	0.5 cc other (q 4	*Soft soap, dietary*	Discrete

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
		toxoid	days)	*1.0 ml q 4 days. Soft soap, dietary discretion, clean nails.*		days)	*discretion, clean nails.*	
N.04.01	**297**	**Hydrocortisone**	4 % topical bid.		**Vehicle**	No dose information		Discrete
		Chloramphenicol	4 % topical bid.					
N.04.02	**224**	**Buttoxethyl nicotinate**	No dose information.	*Normal skin toilet.*	**Vehicle**	No dose information		Continuous Discrete
		Hydrocortisone	No dose information.					
		Chloramphenicol	No dose information.					
		Sulphur	No dose information.					
N.04.03	**142**	**Hydrocortisone**	4 % topical qhs.	*Normal skin toilet.*	**Sulphur**	32 % topical qhs.	*Normal skin toilet.*	Continuous Discrete
		Sulphur	32 % topical qhs.		**Chloramphenicol**	4 % topical qhs.		
		Chloramphenicol	4 % topical qhs.					
N.04.04	**115**	**Sulphur**	32 % topical qhs.	*Bid for first 4 days.*	**Sulphur**	32 % topical qhs.	*Bid for first 4 days.*	Continuous Discrete
		Hydrocortisone	4 % topical qhs.		**Hydrocortisone**	4 % topical qhs.		
		Chloramphenicol	4 % topical qhs.					
N.04.05	**75**	**Sulphur**	No dose information.		**Benzoyl peroxide**	5 % topical bid.	*Frequency qd for 1 week then bid.*	Continuous Discrete
		Hydrocortisone	No dose information.					
		Chloramphenicol	No dose information.					
N.05.01	**138**	**Grenz rays**	1600 rad other (tiw)	*100 rad 3 times a week until dose achieve.*	**Placebo**	No dose information	*Same set-up as Grenz arm, but with lead plate blocking radiation.*	Discrete
	139	**Grenz rays**	2400 rad topical (tiw)	*1600 rads initially, 4-8 week pause, then 800 rads.*	**Placebo**	No dose information	*Same set-up as Grenz arm, but with lead plate blocking radiation.*	Discrete
	179	**Grenz rays**	1200 rad other qd.	*10 kv irradiation frequency 100 rad qd x 6 then 100 rad or 300 rad 9 week x 4.*	**Placebo**	No dose information		Discrete

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
N.05.01	**180**	**Grenz rays**	1200 rad other qd.	*50k irritation frequency 100 rad qd x 6 then 100 rad qwh x 6 or 300 rad 9 weeks x 4.*	**Placebo**	No dose information		Discrete
	350	**Grenz rays**	200 rads other (monthly)		**Hexachlorophene** **Placebo**	No dose information No dose information		(M)
N.05.02	**215**	**Comedone extraction**	No dose information.	*Only right side treated. Some on oral antibiotics or Vitamin A.*	**Comedone extraction**	No dose information	*Only right side treated. Some on oral antibiotics or Vitamin A.*	Discrete
	216	**Comedone extraction**	No dose information.	*Only right side treated. Some on oral antibiotics or Vitamin A.*	**Untreated**	No dose information		Discrete
N.05.03	**31**			*EMLA topical anaesthetic 90 min prior to treatment. 4 patients tab oral anti-bacterials..*	**Tretinoin**	0.025 % topical bid.	*Treatment frequency varied between qd and bid, depending on patient's tolerance. 4 patients oral anti-bacterial..*	Continuous Discrete
N.05.04	**32**			*No topical anaesthetic..*			*Topical anesthesia..*	Continuous
N.06.02	**109**	**Benzoyl peroxide**	No dose information.	*Signed a commitment to medications use and a chance to win $1 for every self monitoring card returned.*	**Benzoyl peroxide**	No dose information	*Asked to keep a record of use of the benzoyl peroxide.*	Continuous (M)
N.06.03	**172**	**Erythromycin** **Benzoyl peroxide** **Relaxation-imagery**	No dose information. No dose information. No dose information.	*The first two sessions were biofeedback-assisted relaxation training. The third and fourth were biofeedback-assisted cue-controlled relaxation training. Session 5 though 12 were biofeedback assisted cue-controlled relaxation and guided*	**Erythromycin** **Benzoyl peroxide**	No dose information No dose information	*No treatment other than standard care at the clinic was administered in this group. This arm was "constructed" retrospectively and were not directly involved in the study.. Topical benzoyl*	Continuous

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
				cognitive imagery training.. Topical benzoyl peroxide and sulfur lotion, topical erythromycin ointment, and attendance at the clinic for lesion extraction..			*peroxide and sulfur lotion, topical erythromycin ointment, and attendance at the clinic for lesion extraction..*	
N.06.04	**178**	**Hydrochlorthiazide**	50 mg oral bid.	*Continued baseline ancillary treatment.*	**Vehicle**	No dose information	*Continued baseline ancillary treatment.*	Discrete
	284	**Hydrochlorthiazide**	25 mg oral tid.	*Soap washing tid; astringent; nightly use of a sulfur ointment.*	**Placebo**	No dose information		Discrete
N.06.045	**349**	**Placebo** **Ibuprofen**	No dose information. 600 mg oral qid.	*Placebo of Tetracycline.*	**Placebo (ibuprofen)** **Placebo**	No dose information No dose information	*Tetragel® placebo + ibuprofen placebo.*	Continuous (M) Discrete
N.06.05	**110**	**Tolbutamide**	No dose information.	*No change of topical therapy was made.*	**Vehicle**	No dose information	*No change of topical therapy was made.*	Discrete
N.07.01	**64**	**Zinc sulfate**	2 % topical tid.		**Vehicle**	No dose information		Continuous
N.07.02	**3**	**Zinc sulfate**	220 mg oral bid.	*After meals.*	**Placebo**	No dose information	*After meals.*	Continuous Discrete
	91	**Zinc gluconate**	200 mg oral qd.	*2 capsules 20 minutes before breakfast.*	**Placebo**	No dose information	*2 capsules 20 minutes before breakfast.*	Continuous Discrete
	133	**Zinc sulphur**	45 mg oral tid.		**Placebo**	No dose information	*Identical in behavior to zinc.*	Continuous Discrete
	163	**Zinc sulfate**	0.2 g oral bid.	*Dosage corresponds to 45 mg zn 2+. Local treatment with salicylic acid &/or liniment of sulfur corresponds to 45 mg zn 2+.*	**Placebo**	No dose information		Continuous Discrete
	211	**Zinc sulfate**	600 mg oral qd.		**Placebo**			Continuous
	259	**Zinc sulfate monohydrate**	137 mg oral tid.	*4 week washout period with placebo. Bland soap, diet low in zinc.*	**Vehicle**	No dose information	*4 week washout period with placebo. Bland soap, diet low in zinc.*	Continuous
	336	**Zinc sulfate**	300 mg oral bid.	*Dose of 300mg report*	**Vehicle**	300 mg oral bid.		Continuous

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
				represents weight of unknown amount of zinc plus lactose.				Discrete
	341	**Zinc sulfate**	220 mg oral tid.	*Usual soaps, OTC meds except benzoyl peroxide.*	**Placebo**	No dose information		Continuous Discrete
	342	**Zinc sulfate**	0.2 g oral tid.	*Tablet dissolved in water three times a day after meals.*	**Vehicle**	No dose information	*Tablet dissolved in water three times a day after meals; identical appearance and taste to treatment.*	Continuous Discrete
N.07.03	**74**	**Zinc sulfate/citrate complex**	No dose information.	*No dose given: "1 three times daily".*	**Tetracycline**	250 mg oral bid.		Continuous
	232	**Zinc sulfate**	0.2 gm oral tid.		**Oxytetracycline**	250 mg oral qd.	*Tid 2 wks; bid 2 wks; qd 8wks.*	Continuous
N.08.01	**108**	**Placebo (oral)** **Zinc acetate** **Erythromycin**	No dose information. 1.2 % topical bid. 4 % topical bid.		**Placebo (oral)** **Placebo (topical)**	No dose information No dose information		Continuous (M)
	301	**Zinc** **Erythromycin**	1.2 % topical bid. 4 % topical bid.		**Vehicle**	No dose information	*Switched to erythro + zinc after 12 weeks.*	Continuous Discrete
	321	**Zinc acetate**	1.2 % topical bid.	*Single product.*	**Vehicle**	No dose information	*Vehicle diisopropyl sebacate 27%.*	Continuous
N.08.02	**28**	**Zinc acetate** **Erythromycin**	No dose information. No dose information.	*Plain soap/cleansing.*	**Erythromycin**	4 % topical bid.	*Plain soap/cleansing.*	Continuous
	147	**Zinc** **Erythromycin**	No dose information. 4 % topical bid.		**Erythromycin**	2 % topical bid.		Continuous Discrete
N.08.03	**300**	**Zinc** **Erythromycin**	1.2 % topical bid. 4 % topical bid.		**Clindamycin phosphate**	1 % topical bid.		Continuous Discrete

"(M)" indicates that data are found on the Multi-Arm tables.